Pediatric Migraine
In pediatric age, diagnosis of migraine can be complex
Medical history taking is often less precise than in adults, both due to the difficulty in describing the symptoms, and because the clinical characteristics of headache can be atypical or superimposable to those of tension headache. Pediatric forms tend to have shorter duration and bilateral localization more frequent than adults, as reported by the International Headache Society in ICHD-3.
The guidelines of the American Academy of Neurology underline that, in the pediatric field, the pharmacological options for prevention are very limited compared to adulthood and with sometimes modest levels of evidence. The treatment of the acute attack must also be carefully modulated in terms of age, weight and safety profile.
The impact of headache in developmental age is often underestimated. Clinical studies show that pediatric migraines can interfere with school attendance, sports activities and social relationships, helping to generate anticipatory anxiety and reduction of quality of life.
Role of nutraceuticals
In this context, some clinicians resort to dietary supplements as a support in the management of primary headache. Products based on magnesium, feverfew, vitamin B2 and other substances are used in clinical practice, although the scientific evidence in children is limited and less robust than that available for adults.
These include AuraSTOP, which, as part of a healthy lifestyle, is used to support the management of tension headaches and migraine. It is important to clarify that, although it is a dietary supplement and not a pharmaceutical drug, this does not automatically rule out potential side effects or interactions—which is why it should only be used under pediatric or specialist supervision.
When to use AuraSTOP
AuraSTOP can be used as part of a healthy lifestyle as a support for patients suffering from headache disorders, in particular in migraine with or without aura both continuously and at the time of the attack.
Continuous use
AuraSTOP may be used continuously in children, upon medical advice, at a dosage of 1 sachet twice daily for 2–3 months. Continuous use aims to reduce the frequency, intensity, and duration of episodes. If clinical benefit is achieved, the cycle may be repeated after a few months without supplementation, if necessary.
Continuous use is particularly beneficial for children with frequent attacks (3–4 episodes per month), a significant impact on quality of life or school performance, and a poor response or intolerance to acute medications.
Use During an Acute Attack
In children over 4 years of age, AuraSTOP may be used as a supportive measure during acute attacks, at a dosage of 1 sachet upon the onset of the first symptoms.
Always as part of a healthy lifestyle and thanks to its formulation based on Magnesium, Feverfew, and Griffonia extracts, AuraSTOP can help attenuate visual or somatosensory phenomena, likely due to the synergistic action of its components on mitochondrial metabolism, oxidative stress, and neurovascular mechanisms involved in migraines.
Dosage
AuraSTOP represents a natural support for these conditions at such a delicate age. Given the limited number of well-known and studied pharmacological approaches in this age group, AuraSTOP offers a new tool for pediatricians and child neuropsychiatrists when managing tension-type headaches and migraines.